Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Emergent BioSolutions price target raised to $55 from $50 at Cantor Fitzgerald » 07:51
01/20/22
01/20
07:51
01/20/22
07:51
EBS

Emergent BioSolutions

$45.52 /

-1.91 (-4.03%)

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Brandon Folkes raised the firm's price target on Emergent BioSolutions to $55 from $50 and keeps an Overweight rating on the shares. The price target revision is driven by marginally increased visibility on the company's longer-term topline growth profile, and as well as a greater appreciation for near-term cash generation, Folkes tells investors in a research note. At the same time, the analyst believes that the 2022 guidance is not an all clearing event for the overhangs that remain.

ShowHide Related Items >><<
EBS Emergent BioSolutions
$45.52 /

-1.91 (-4.03%)

EBS Emergent BioSolutions
$45.52 /

-1.91 (-4.03%)

01/20/22 Benchmark
Emergent BioSolutions upgraded to Buy from Hold at Benchmark
12/27/21 Cowen
Emergent's Narcan sales under immediate threat, says Cowen
11/10/21 Chardan
Emergent BioSolutions price target lowered to $75 from $92 at Chardan
11/08/21 Benchmark
Emergent BioSolutions cut to Hold at Benchmark on loss of government contract
EBS Emergent BioSolutions
$45.52 /

-1.91 (-4.03%)

EBS Emergent BioSolutions
$45.52 /

-1.91 (-4.03%)

EBS Emergent BioSolutions
$45.52 /

-1.91 (-4.03%)

Upgrade
Emergent BioSolutions upgraded to Buy from Hold at Benchmark » 06:27
01/20/22
01/20
06:27
01/20/22
06:27
EBS

Emergent BioSolutions

$45.52 /

-1.91 (-4.03%)

Benchmark analyst Robert…

Benchmark analyst Robert Wasserman upgraded Emergent BioSolutions to Buy from Hold with a $77 price target, which represents 60% appreciation from the current share price. He cites what he views as an improved outlook for 2022, including an expected rebound in contract development and manufacturing revenues and a "brighter" short-term outlook for nasal naloxone product sales following a milder generic launch.

ShowHide Related Items >><<
EBS Emergent BioSolutions
$45.52 /

-1.91 (-4.03%)

EBS Emergent BioSolutions
$45.52 /

-1.91 (-4.03%)

12/27/21 Cowen
Emergent's Narcan sales under immediate threat, says Cowen
11/10/21 Chardan
Emergent BioSolutions price target lowered to $75 from $92 at Chardan
11/08/21 Benchmark
Emergent BioSolutions cut to Hold at Benchmark on loss of government contract
11/08/21 Benchmark
Emergent BioSolutions downgraded to Hold from Buy at Benchmark
EBS Emergent BioSolutions
$45.52 /

-1.91 (-4.03%)

EBS Emergent BioSolutions
$45.52 /

-1.91 (-4.03%)

EBS Emergent BioSolutions
$45.52 /

-1.91 (-4.03%)

Over a week ago
Hot Stocks
Emergent BioSolutions founder and executive chairman, Fuad El-Hibri, to retire » 06:41
01/14/22
01/14
06:41
01/14/22
06:41
EBS

Emergent BioSolutions

$49.53 /

+1.01 (+2.08%)

Emergent BioSolutions…

Emergent BioSolutions announced that Fuad El-Hibri, founder and executive chairman, has decided to retire effective April 1. Given El-Hibri's wisdom, knowledge, experience, and history with the company, Emergent anticipates that El-Hibri will still be available as needed to effectively transition his knowledge to the Board of Directors and management team. The details of any arrangement related to that are under consideration by the Emergent Board of Directors and will be disclosed when approved by the Board. Emergent expects to name a new Chair of the Board of Directors ahead of El-Hibri's retirement.

ShowHide Related Items >><<
EBS Emergent BioSolutions
$49.53 /

+1.01 (+2.08%)

EBS Emergent BioSolutions
$49.53 /

+1.01 (+2.08%)

12/27/21 Cowen
Emergent's Narcan sales under immediate threat, says Cowen
11/10/21 Chardan
Emergent BioSolutions price target lowered to $75 from $92 at Chardan
11/08/21 Benchmark
Emergent BioSolutions cut to Hold at Benchmark on loss of government contract
11/08/21 Benchmark
Emergent BioSolutions downgraded to Hold from Buy at Benchmark
EBS Emergent BioSolutions
$49.53 /

+1.01 (+2.08%)

EBS Emergent BioSolutions
$49.53 /

+1.01 (+2.08%)

EBS Emergent BioSolutions
$49.53 /

+1.01 (+2.08%)

Earnings
Emergent BioSolutions sees preliminary FY21 revenue $1.78B, consensus $1.7B » 14:55
01/09/22
01/09
14:55
01/09/22
14:55
EBS

Emergent BioSolutions

$48.84 /

+0.47 (+0.97%)

Emergent BioSolutions…

Emergent BioSolutions reported preliminary 2021 total revenues of $1.78 billion at the midpoint and Adjusted EBITDA of $513 million, or 29%, at the midpoint, both in line with prior guidance given in November 202. The company expects a re-baseline of operations with stable revenue contributions from core products and services business in 2022, guiding to total revenues of $1.45 billion at the midpoint and Adjusted EBITDA margin of 21.5% at the midpoint.

ShowHide Related Items >><<
EBS Emergent BioSolutions
$48.84 /

+0.47 (+0.97%)

EBS Emergent BioSolutions
$48.84 /

+0.47 (+0.97%)

12/27/21 Cowen
Emergent's Narcan sales under immediate threat, says Cowen
11/10/21 Chardan
Emergent BioSolutions price target lowered to $75 from $92 at Chardan
11/08/21 Benchmark
Emergent BioSolutions cut to Hold at Benchmark on loss of government contract
11/08/21 Benchmark
Emergent BioSolutions downgraded to Hold from Buy at Benchmark
EBS Emergent BioSolutions
$48.84 /

+0.47 (+0.97%)

EBS Emergent BioSolutions
$48.84 /

+0.47 (+0.97%)

EBS Emergent BioSolutions
$48.84 /

+0.47 (+0.97%)

Recommendations
Emergent's Narcan sales under immediate threat, says Cowen » 08:26
12/27/21
12/27
08:26
12/27/21
08:26
EBS

Emergent BioSolutions

$45.54 /

+0.745 (+1.66%)

Cowen analyst Boris…

Cowen analyst Boris Peaker keeps a Market Perform rating on Emergent BioSolutions with a $67 price target after the company reported that a generic naloxone has entered the market. The generic entry timing is earlier than expected, says the analyst, who anticipates revenue and margin erosion for Emergent over the next several years. Peaker thinks the company's authorized generic with Sandoz "is unlikely to help much" and that Narcan sales will be threatened "immediately."

ShowHide Related Items >><<
EBS Emergent BioSolutions
$45.54 /

+0.745 (+1.66%)

EBS Emergent BioSolutions
$45.54 /

+0.745 (+1.66%)

11/10/21 Chardan
Emergent BioSolutions price target lowered to $75 from $92 at Chardan
11/08/21 Benchmark
Emergent BioSolutions cut to Hold at Benchmark on loss of government contract
11/08/21 Benchmark
Emergent BioSolutions downgraded to Hold from Buy at Benchmark
07/29/21 Benchmark
Emergent BioSolutions' catalysts 'falling into place,' says Benchmark
EBS Emergent BioSolutions
$45.54 /

+0.745 (+1.66%)

EBS Emergent BioSolutions
$45.54 /

+0.745 (+1.66%)

EBS Emergent BioSolutions
$45.54 /

+0.745 (+1.66%)

Over a month ago
Hot Stocks
Emergent BioSolutions initiates of Phase 1 study of influenza vaccine candidate » 07:35
12/16/21
12/16
07:35
12/16/21
07:35
EBS

Emergent BioSolutions

$42.24 /

+1.37 (+3.35%)

Emergent BioSolutions…

Emergent BioSolutions announced the first participant dosed in its phase 1 study, EBS-UFV-001, evaluating the safety, tolerability, and immunogenicity of the company's investigational universal influenza vaccine candidate. This current version of Emergent's universal influenza vaccine candidate contains multiple components intended to induce broad and supra-seasonal immunity against influenza A viruses. "Emergent remains focused on investing in our diverse portfolio of R&D programs targeting infectious disease and other public health threats," said Kelly Warfield, Ph.D., senior vice president, research and development at Emergent BioSolutions. "Initiating this phase 1 study demonstrates our commitment to advancing our pipeline and our research and development team's scientific prowess to adopt an innovative technology and investigate a potential vaccine candidate for a disease that affects millions every year." The goal of this single-center, randomized, double blind, placebo-controlled dose-escalation study is to evaluate the safety, tolerability, and immunogenicity of the vaccine candidate at two dose levels and two schedules in 60 healthy adult individuals aged 18 to 45. This phase 1 study, being conducted in Australia, is fully funded by Emergent.

ShowHide Related Items >><<
EBS Emergent BioSolutions
$42.24 /

+1.37 (+3.35%)

EBS Emergent BioSolutions
$42.24 /

+1.37 (+3.35%)

11/10/21 Chardan
Emergent BioSolutions price target lowered to $75 from $92 at Chardan
11/08/21 Benchmark
Emergent BioSolutions cut to Hold at Benchmark on loss of government contract
11/08/21 Benchmark
Emergent BioSolutions downgraded to Hold from Buy at Benchmark
07/29/21 Benchmark
Emergent BioSolutions' catalysts 'falling into place,' says Benchmark
EBS Emergent BioSolutions
$42.24 /

+1.37 (+3.35%)

EBS Emergent BioSolutions
$42.24 /

+1.37 (+3.35%)

EBS Emergent BioSolutions
$42.24 /

+1.37 (+3.35%)

Conference/Events
Emergent BioSolutions participates in a conference call with JPMorgan » 13:25
12/01/21
12/01
13:25
12/01/21
13:25
EBS

Emergent BioSolutions

$44.15 /

+0.05 (+0.11%)

SMid Cap Biotech Analyst…

SMid Cap Biotech Analyst Fye holds a conference call with CEO Kramer and CFO Lindahl on December 1 at 2 pm hosted by JPMorgan.

ShowHide Related Items >><<
EBS Emergent BioSolutions
$44.15 /

+0.05 (+0.11%)

EBS Emergent BioSolutions
$44.15 /

+0.05 (+0.11%)

11/10/21 Chardan
Emergent BioSolutions price target lowered to $75 from $92 at Chardan
11/08/21 Benchmark
Emergent BioSolutions cut to Hold at Benchmark on loss of government contract
11/08/21 Benchmark
Emergent BioSolutions downgraded to Hold from Buy at Benchmark
07/29/21 Benchmark
Emergent BioSolutions' catalysts 'falling into place,' says Benchmark
EBS Emergent BioSolutions
$44.15 /

+0.05 (+0.11%)

EBS Emergent BioSolutions
$44.15 /

+0.05 (+0.11%)

EBS Emergent BioSolutions
$44.15 /

+0.05 (+0.11%)

Conference/Events
Emergent BioSolutions participates in a conference call with JPMorgan » 04:55
12/01/21
12/01
04:55
12/01/21
04:55
EBS

Emergent BioSolutions

$44.16 /

+2.08 (+4.94%)

SMid Cap Biotech Analyst…

SMid Cap Biotech Analyst Fye holds a conference call with CEO Kramer and CFO Lindahl on December 1 at 2 pm hosted by JPMorgan.

ShowHide Related Items >><<
EBS Emergent BioSolutions
$44.16 /

+2.08 (+4.94%)

EBS Emergent BioSolutions
$44.16 /

+2.08 (+4.94%)

11/10/21 Chardan
Emergent BioSolutions price target lowered to $75 from $92 at Chardan
11/08/21 Benchmark
Emergent BioSolutions cut to Hold at Benchmark on loss of government contract
11/08/21 Benchmark
Emergent BioSolutions downgraded to Hold from Buy at Benchmark
07/29/21 Benchmark
Emergent BioSolutions' catalysts 'falling into place,' says Benchmark
EBS Emergent BioSolutions
$44.16 /

+2.08 (+4.94%)

EBS Emergent BioSolutions
$44.16 /

+2.08 (+4.94%)

EBS Emergent BioSolutions
$44.16 /

+2.08 (+4.94%)

Conference/Events
Emergent BioSolutions participates in a conference call with JPMorgan » 17:04
11/30/21
11/30
17:04
11/30/21
17:04
EBS

Emergent BioSolutions

$44.16 /

+2.08 (+4.94%)

SMid Cap Biotech Analyst…

SMid Cap Biotech Analyst Fye holds a conference call with CEO Kramer and CFO Lindahl on December 1 at 2 pm hosted by JPMorgan.

ShowHide Related Items >><<
EBS Emergent BioSolutions
$44.16 /

+2.08 (+4.94%)

EBS Emergent BioSolutions
$44.16 /

+2.08 (+4.94%)

11/10/21 Chardan
Emergent BioSolutions price target lowered to $75 from $92 at Chardan
11/08/21 Benchmark
Emergent BioSolutions cut to Hold at Benchmark on loss of government contract
11/08/21 Benchmark
Emergent BioSolutions downgraded to Hold from Buy at Benchmark
07/29/21 Benchmark
Emergent BioSolutions' catalysts 'falling into place,' says Benchmark
EBS Emergent BioSolutions
$44.16 /

+2.08 (+4.94%)

EBS Emergent BioSolutions
$44.16 /

+2.08 (+4.94%)

EBS Emergent BioSolutions
$44.16 /

+2.08 (+4.94%)

Hot Stocks
Emergent BioSolutions to replace Domtar in S&P 600 at open on 11/30 » 04:55
11/30/21
11/30
04:55
11/30/21
04:55
EBS

Emergent BioSolutions

$42.08 /

-2.23 (-5.03%)

, UFS

Domtar

$55.49 /

+0.01 (+0.02%)

Paper Excellence B.V. is…

Paper Excellence B.V. is acquiring Domtar in a deal expected to be completed soon pending final conditions.

ShowHide Related Items >><<
UFS Domtar
$55.49 /

+0.01 (+0.02%)

EBS Emergent BioSolutions
$42.08 /

-2.23 (-5.03%)

EBS Emergent BioSolutions
$42.08 /

-2.23 (-5.03%)

11/10/21 Chardan
Emergent BioSolutions price target lowered to $75 from $92 at Chardan
11/08/21 Benchmark
Emergent BioSolutions cut to Hold at Benchmark on loss of government contract
11/08/21 Benchmark
Emergent BioSolutions downgraded to Hold from Buy at Benchmark
07/29/21 Benchmark
Emergent BioSolutions' catalysts 'falling into place,' says Benchmark
UFS Domtar
$55.49 /

+0.01 (+0.02%)

07/16/21 BMO Capital
Domtar downgraded to Market Perform from Outperform at BMO Capital
07/06/21 TD Securities
Domtar downgraded to Tender from Hold at TD Securities
05/07/21 RBC Capital
Domtar price target raised to $43 from $40 at RBC Capital
05/07/21 BMO Capital
Domtar price target raised to $53 from $40 at BMO Capital
EBS Emergent BioSolutions
$42.08 /

-2.23 (-5.03%)

EBS Emergent BioSolutions
$42.08 /

-2.23 (-5.03%)

EBS Emergent BioSolutions
$42.08 /

-2.23 (-5.03%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.